U.S. Markets open in 3 hrs 48 mins

Immuron Limited (IMRN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7500+0.0100 (+0.36%)
At close: 04:00PM EDT
2.6000 -0.15 (-5.45%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.7400
Bid0.0000 x 1300
Ask0.0000 x 900
Day's Range2.6699 - 2.9097
52 Week Range2.3200 - 5.2000
Avg. Volume14,120
Market Cap16.651M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-1.0800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

    Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea caused by ETEC and scheduled to be initiated in July 2022.The second trial will focus on protecting volunteers against moderate to severe campylobacteriosis. MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX

  • GlobeNewswire

    US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™

    UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the comparative efficacy of Travelan® with two third party non-antibiotic OTC products in Travelers’ DiarrheaThe treatment period in the clinical protocol has been extended from 13 days to 22 days, to accommodate COVID-19 quarantine period requirements during travelInitial shipments of investigational medicinal p

  • GlobeNewswire

    Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer

    MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA.